Cargando…

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Takumi, Tomita, Kengo, Kawai, Toshihide, Yokoyama, Hirokazu, Shimada, Akira, Kikuchi, Masahiro, Hirose, Hiroshi, Ebinuma, Hirotoshi, Irie, Junichiro, Ojiro, Keisuke, Oikawa, Yoichi, Saito, Hidetsugu, Itoh, Hiroshi, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755443/
https://www.ncbi.nlm.nih.gov/pubmed/23997767
http://dx.doi.org/10.1155/2013/587140
_version_ 1782281993905504256
author Hirata, Takumi
Tomita, Kengo
Kawai, Toshihide
Yokoyama, Hirokazu
Shimada, Akira
Kikuchi, Masahiro
Hirose, Hiroshi
Ebinuma, Hirotoshi
Irie, Junichiro
Ojiro, Keisuke
Oikawa, Yoichi
Saito, Hidetsugu
Itoh, Hiroshi
Hibi, Toshifumi
author_facet Hirata, Takumi
Tomita, Kengo
Kawai, Toshihide
Yokoyama, Hirokazu
Shimada, Akira
Kikuchi, Masahiro
Hirose, Hiroshi
Ebinuma, Hirotoshi
Irie, Junichiro
Ojiro, Keisuke
Oikawa, Yoichi
Saito, Hidetsugu
Itoh, Hiroshi
Hibi, Toshifumi
author_sort Hirata, Takumi
collection PubMed
description Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.
format Online
Article
Text
id pubmed-3755443
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37554432013-09-01 Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY) Hirata, Takumi Tomita, Kengo Kawai, Toshihide Yokoyama, Hirokazu Shimada, Akira Kikuchi, Masahiro Hirose, Hiroshi Ebinuma, Hirotoshi Irie, Junichiro Ojiro, Keisuke Oikawa, Yoichi Saito, Hidetsugu Itoh, Hiroshi Hibi, Toshifumi Int J Endocrinol Clinical Study Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver. Hindawi Publishing Corporation 2013 2013-08-13 /pmc/articles/PMC3755443/ /pubmed/23997767 http://dx.doi.org/10.1155/2013/587140 Text en Copyright © 2013 Takumi Hirata et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Hirata, Takumi
Tomita, Kengo
Kawai, Toshihide
Yokoyama, Hirokazu
Shimada, Akira
Kikuchi, Masahiro
Hirose, Hiroshi
Ebinuma, Hirotoshi
Irie, Junichiro
Ojiro, Keisuke
Oikawa, Yoichi
Saito, Hidetsugu
Itoh, Hiroshi
Hibi, Toshifumi
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title_full Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title_fullStr Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title_full_unstemmed Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title_short Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
title_sort effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by telmisartan or losartan study (fantasy)
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755443/
https://www.ncbi.nlm.nih.gov/pubmed/23997767
http://dx.doi.org/10.1155/2013/587140
work_keys_str_mv AT hiratatakumi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT tomitakengo effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT kawaitoshihide effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT yokoyamahirokazu effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT shimadaakira effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT kikuchimasahiro effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT hirosehiroshi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT ebinumahirotoshi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT iriejunichiro effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT ojirokeisuke effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT oikawayoichi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT saitohidetsugu effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT itohhiroshi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy
AT hibitoshifumi effectoftelmisartanorlosartanfortreatmentofnonalcoholicfattyliverdiseasefattyliverprotectiontrialbytelmisartanorlosartanstudyfantasy